8-Epitacrolimus

8-Epitacrolimus is a derivative of tacrolimus, a potent immunosuppressive drug used in organ transplantation and autoimmune diseases. It is a synthetic compound that has been modified to have increased potency and selectivity compared to the parent drug. The usage of 8-Epitacrolimus is mainly in the treatment of inflammatory skin diseases such as atopic dermatitis, psoriasis, and eczema. It works by inhibiting the activation of T-cells and preventing the release of inflammatory cytokines, thus reducing the inflammation and symptoms associated with these skin conditions. Chemically, 8-Epitacrolimus is a macrolide lactone with a molecular weight of 822.02 g/mol. It has a similar structure to tacrolimus, with the addition of a methyl group at position 8 of the macrolide ring. This modification enhances the drug's potency and selectivity, as it allows for better binding to the FKBP12 protein, which is the target of tacrolimus. 8-Epitacrolimus has been shown to have a higher affinity for the FKBP12 protein than tacrolimus, which results in a more potent immunosuppressive effect. It has also been found to have less toxicity and fewer side effects than tacrolimus, making it a promising candidate for the treatment of inflammatory skin diseases. In conclusion, 8-Epitacrolimus is a synthetic compound derived from tacrolimus that is used in the treatment of inflammatory skin diseases. Its chemical structure has been modified to increase its potency and selectivity, resulting in a more effective and safer drug.